Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | ELANE | P08246 | 2/20 | 0.46 |
| ▸ | CASP3 | P42574 | 1/20 | 0.46 |
| ▸ | CASP1 | P29466 | 6/20 | 0.46 |
| ▸ | CTSK | P43235 | 4/20 | 0.45 |
| ▸ | CTSL | P07711 | 2/20 | 0.45 |
| ▸ | CTSB | P07858 | 2/20 | 0.45 |
| ▸ | CTSS | P25774 | 2/20 | 0.45 |
| ▸ | PRTN3 | P24158 | 1/20 | 0.44 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2501207 | 0.91 | ATM (0.47) | ATMELANECTSKCTSLCTSB | |
| SCHEMBL3276084 | 0.85 | ATM (0.49) | ATMELANECASP3CASP1CTSK | |
| SCHEMBL14493005 | 0.81 | ATM (0.39) | ATMELANECASP1CTSKCTSL | |
| SCHEMBL12906609 | 0.81 | ATM (0.61) | ATMELANECTSKCTSLCTSB | |
| SCHEMBL3338883 | 0.80 | ATM (0.52) | ATMELANECASP3CASP1CTSK | |
| SCHEMBL3274393 | 0.80 | ATM (0.52) | ATMELANECASP3CASP1CTSK | |
| SCHEMBL3339842 | 0.80 | ATM (0.52) | ATMELANECASP3CASP1CTSK | |
| SCHEMBL19859590 | 0.76 | ATM (0.56) | ATMELANECASP3CASP1CTSK | |
| SCHEMBL9749127 | 0.76 | ATM (0.56) | ATMELANECASP3CASP1CTSK | |
| SCHEMBL3202235 | 0.76 | ATM (0.56) | ATMELANECASP3CASP1CTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8030279-B2 | Tamandarin analogs and fragments thereof and methods of making and using | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2011-10-04 | — | — | US | disclosed |
| US-20070149446-A1 | Tamandarin analogs and fragments thereof and methods of making and using | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA CENTER FOR TECHNOLOGY TRANSFER (US) | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149446-A1 | Tamandarin analogs and fragments thereof and methods of making and using | FOXM1, F3, RB1 | ATM 1572/4885ELANE 1539/4885CASP3 331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.